TY - JOUR
T1 - Role of microRNA Shuttled in Small Extracellular Vesicles Derived From Mesenchymal Stem/Stromal Cells for Osteoarticular Disease Treatment
AU - Lara-Barba, Eliana
AU - Araya, María Jesús
AU - Hill, Charlotte Nicole
AU - Bustamante-Barrientos, Felipe A.
AU - Ortloff, Alexander
AU - García, Cynthia
AU - Galvez-Jiron, Felipe
AU - Pradenas, Carolina
AU - Luque-Campos, Noymar
AU - Maita, Gabriela
AU - Elizondo-Vega, Roberto
AU - Djouad, Farida
AU - Vega-Letter, Ana María
AU - Luz-Crawford, Patricia
N1 - Publisher Copyright:
© Copyright © 2021 Lara-Barba, Araya, Hill, Bustamante-Barrientos, Ortloff, García, Galvez-Jiron, Pradenas, Luque-Campos, Maita, Elizondo-Vega, Djouad, Vega-Letter and Luz-Crawford.
Copyright © 2021 Lara-Barba, Araya, Hill, Bustamante-Barrientos, Ortloff, García, Galvez-Jiron, Pradenas, Luque-Campos, Maita, Elizondo-Vega, Djouad, Vega-Letter and Luz-Crawford.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Osteoarticular diseases (OD), such as rheumatoid arthritis (RA) and osteoarthritis (OA) are chronic autoimmune/inflammatory and age-related diseases that affect the joints and other organs for which the current therapies are not effective. Cell therapy using mesenchymal stem/stromal cells (MSCs) is an alternative treatment due to their immunomodulatory and tissue differentiation capacity. Several experimental studies in numerous diseases have demonstrated the MSCs’ therapeutic effects. However, MSCs have shown heterogeneity, instability of stemness and differentiation capacities, limited homing ability, and various adverse responses such as abnormal differentiation and tumor formation. Recently, acellular therapy based on MSC secreted factors has raised the attention of several studies. It has been shown that molecules embedded in extracellular vesicles (EVs) derived from MSCs, particularly those from the small fraction enriched in exosomes (sEVs), effectively mimic their impact in target cells. The biological effects of sEVs critically depend on their cargo, where sEVs-embedded microRNAs (miRNAs) are particularly relevant due to their crucial role in gene expression regulation. Therefore, in this review, we will focus on the effect of sEVs derived from MSCs and their miRNA cargo on target cells associated with the pathology of RA and OA and their potential therapeutic impact.
AB - Osteoarticular diseases (OD), such as rheumatoid arthritis (RA) and osteoarthritis (OA) are chronic autoimmune/inflammatory and age-related diseases that affect the joints and other organs for which the current therapies are not effective. Cell therapy using mesenchymal stem/stromal cells (MSCs) is an alternative treatment due to their immunomodulatory and tissue differentiation capacity. Several experimental studies in numerous diseases have demonstrated the MSCs’ therapeutic effects. However, MSCs have shown heterogeneity, instability of stemness and differentiation capacities, limited homing ability, and various adverse responses such as abnormal differentiation and tumor formation. Recently, acellular therapy based on MSC secreted factors has raised the attention of several studies. It has been shown that molecules embedded in extracellular vesicles (EVs) derived from MSCs, particularly those from the small fraction enriched in exosomes (sEVs), effectively mimic their impact in target cells. The biological effects of sEVs critically depend on their cargo, where sEVs-embedded microRNAs (miRNAs) are particularly relevant due to their crucial role in gene expression regulation. Therefore, in this review, we will focus on the effect of sEVs derived from MSCs and their miRNA cargo on target cells associated with the pathology of RA and OA and their potential therapeutic impact.
KW - mesenchymal stem cells
KW - microRNA
KW - osteoarthritis
KW - rheumatoid arthritis
KW - small extracellular vesicles
UR - http://www.scopus.com/inward/record.url?scp=85119282616&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/9cf51fad-895e-382a-bef3-749942ed40e4/
U2 - 10.3389/fimmu.2021.768771
DO - 10.3389/fimmu.2021.768771
M3 - Review article
C2 - 34790203
AN - SCOPUS:85119282616
SN - 1664-3224
VL - 12
SP - 768771
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 768771
ER -